Jameel Health strengthens position, announces new international commercial network

• Locally respected partners appointed for key markets including Turkey, India, Oman, Kuwait, UAE and Saudi Arabia, among others
• Rapidly expanding multi-national network infrastructure delivers on Jameel Health promise of accelerating access to modern medical care across the global south

Jameel Health, part of international diversified family business Abdul Latif Jameel, has announced the creation of its new international commercial channel, helping to accelerate access to modern medical care and drive health inclusivity across the Global South.

The network of confirmed partners will cover key markets across a wide geographic area including India, Kuwait, Morocco, Oman, Saudi Arabia, Turkey and the UAE, and will see on the ground distribution of Jameel Health approved products into hospitals, clinics and medical institutions to fast-track health inclusion for those who need it most.  Jameel Health is continuing contractual negotiations for partnerships and acquisitions with other important markets and the network will grow over the coming months across Africa, South and Southeast Asia, and Latin America.

Since its launch in 2020, Jameel Health has developed strong relationships with renowned health partners utilizing innovation and industry disruptive approaches to deliver healthcare in more efficient ways.  Partners include Implandata, Eyerising, PlasmaJet, CoapTech, LPIXEL, Genpharm, Cyberdyne, Evelo Biosciences, Melody International and Holoeyes Inc., among others.

Akram Bouchenaki, Chief Executive Officer, Jameel Health said: “The Global South covers a huge geographical area with nations that are diverse and complex, both commercially and culturally.  It is for this reason that it is so important we work with partners who understand their markets intrinsically and can align with the respective regulatory authorities for our range of products and services we are delivering.

“At Jameel Health, we are delivering on our promise of offering an integrated ‘one-stop’ managed service to medical devices, pharmaceutical products, diagnostic and therapeutics manufacturers to afford them multi-market access more rapidly than they could manage individually.  We will distribute their products to the populations that can most benefit from them sooner, meeting unmet medical needs, driving healthcare inclusivity, and in parallel, opening the unrealized commercial potential of these markets.”

Last month, Jameel Health also announced the appointment of three globally respected and renowned scientists as special scientific advisors to join its mission in accelerating access to modern medical care across the Global South.  The advisors are: The Right Hon. Professor Lord Kakkar PC, Director of the Thrombosis Research Institute and Emeritus Professor of Surgery at University College London; Professor James J. Collins, PhD, Termeer Professor of Medical Engineering and Science at the Institute for Medical Engineering & Science (IMES) and Department of Biological Engineering at the Massachusetts Institute of Technology (MIT) and Founder of the Jameel Clinic at MIT; and Professor Charles Coombes, PhD MBBS FRCP MD FMedSci, Professor of Medical Oncology, Imperial College London.

Jameel Health was created in 2020 as a response to the ongoing global disparity in access to modern medical care, focusing on accelerating healthcare inclusion across the Global South.  Reflecting the Jameel Family’s long-established commitment to innovating for a better future, Jameel Health works in the commercial environment to address tangible real-world needs today, for a better tomorrow.  It works with partners from around the world to open and grow new markets for distribution of existing solutions and investing in the future of MedTech.